NASDAQ: UPBUpstream Bio Inc Stock
$11.36-0.20 (-1.73%)
Updated Jun 13, 2025
UPB Price
$11.36
Fair Value Price
-$0.07
Market Cap
$611.10M
52 Week Low
$5.14
52 Week High
$29.46
P/E
N/A
P/B
1.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
N/A
Beta
1.16
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
UPB Overview
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine UPB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
UPB
Ranked#188 of 464
Ranked#188 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important UPB news, forecast changes, insider trades & much more!
UPB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how UPB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UPB ($11.36) is overvalued by 16,655.92% relative to our estimate of its Fair Value price of -$0.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
UPB ($11.36) is not significantly undervalued (16,655.92%) relative to our estimate of its Fair Value price of -$0.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
UPB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more UPB due diligence checks available for Premium users.
Valuation
UPB fair value
Fair Value of UPB stock based on Discounted Cash Flow (DCF)
Price
$11.36
Fair Value
-$0.07
Undervalued by
16,655.92%
UPB ($11.36) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
UPB ($11.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
UPB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-108.97x
Market
31.36x
UPB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.37x
Industry
4.66x
UPB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
UPB's financial health
Profit margin
Revenue
$566.0k
Net Income
-$27.3M
Profit Margin
-4,818%
Assets to liabilities
Assets
$456.2M
Liabilities
$10.6M
Debt to equity
0.02
UPB's short-term assets ($453.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UPB's short-term assets ($453.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UPB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$41.2M
Investing
-$213.4M
Financing
-$34.0k
UPB vs Biotech Stocks
Upstream Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.